Publications and communications of Grégory Ehx

Articles accepted in reviewed journal

Jassin, M.* , E Silva, B.* , Ormenese, S., Baron, F., Ehx, G.* , & Caers, J.*. (13 March 2026). Comparable restimulation of human T cells activated with CD3/CD28 beads versus soluble antibody complexes. Scientific Reports, 16 (1). doi:10.1038/s41598-026-43542-4
* These authors have contributed equally to this work.

Beguin, C.* , Kwan, O.* , Ehx, G., Humblet-Baron, S., Köse, M. C., Dubois, S., Canti, L., Courtois, J., Daulne, C., Caers, J., Beguin, Y., Ritacco, C.* , & Baron, F.*. (11 December 2025). Development of a humanized mouse model of graft-versus-host disease to assess human regulatory T cell function. Frontiers in Immunology, 16. doi:10.3389/fimmu.2025.1717133
* These authors have contributed equally to this work.

Jassin, M., Onkelinx, C., Bocuzzi, V., E Silva, B., Kwan, O., Block, A., Dubois, S., Daulne, C., Marcion, G., Ormenese, S., Di Valentin, E., Baron, F., GREGOIRE, C., Ehx, G., Nguyen, T. T., & Caers, J. (08 December 2025). Comparing a Novel Anti-BCMA NanoCAR with a Conventional ScFv-Based CAR for the Treatment of Multiple Myeloma. Cells, 14 (24), 1944. doi:10.3390/cells14241944

Jassin, M., Block, A., Désiront, L., Vrancken, L., GREGOIRE, C., Baron, F., Ehx, G., Nguyen, T. T., & Caers, J.*. (11 July 2025). From spheroids to organoids: next-generation models for CAR-T cell therapy research in solid tumors. Frontiers in Immunology, 16. doi:10.3389/fimmu.2025.1626369

Apavaloaei, A., Zhao, Q., Hesnard, L., Cahuzac, M., Durette, C., Larouche, J.-D., Hardy, M.-P., Vincent, K., Brochu, S., Laverdure, J.-P., Lanoix, J., Courcelles, M., Gendron, P., Lajoie, M., Ruiz Cuevas, M. V., Kina, E., Perrault, J., Humeau, J., Ehx, G., ... Perreault, C. (2025). Tumor antigens preferentially derive from unmutated genomic sequences in melanoma and non-small cell lung cancer. Nature Cancer. doi:10.1038/s43018-025-00979-2

Faville, C.* , E Silva, B.* , Baron, F., & Ehx, G. (19 March 2025). Use of Human Acute Myeloid Leukemia Cells to Study Graft-Versus-Leukemia Immunity in Xenogeneic Mouse Models of Graft-Versus-Host Disease. Methods in Molecular Biology, 2907, 359 - 375. doi:10.1007/978-1-0716-4430-0_17
* These authors have contributed equally to this work.

Ehx, G., Ritacco, C., & Baron, F. (14 November 2024). Pathophysiology and preclinical relevance of experimental graft-versus-host disease in humanized mice. Biomarker Research, 12 (1), 139. doi:10.1186/s40364-024-00684-9

Noronha, N., Durette, C., Cahuzac, M., E Silva, B., Courtois, J., Humeau, J., Sauvat, A., Hardy, M.-P., Vincent, K., Laverdure, J.-P., Lanoix, J., Baron, F., Thibault, P., Perreault, C., & Ehx, G. (2024). Autophagy degrades immunogenic endogenous retroelements induced by 5-azacytidine in acute myeloid leukemia. Leukemia, 38, 1019-1031. doi:10.1038/s41375-024-02250-6

Cuevas, M. V. R., Hardy, M.-P., Larouche, J.-D., Apavaloaei, A., Kina, E., Vincent, K., Gendron, P., Laverdure, J.-P., Durette, C., Thibault, P.* , Lemieux, S.* , Perreault, C.* , & Ehx, G.*. (15 August 2023). BamQuery: a proteogenomic tool to explore the immunopeptidome and prioritize actionable tumor antigens. Genome Biology, 24 (1), 188. doi:10.1186/s13059-023-03029-1
* These authors have contributed equally to this work.

Guilloy, N., Brunet, M. A., Leblanc, S., Jacques, J.-F., Hardy, M.-P., Ehx, G., Lanoix, J., Thibault, P., Perreault, C., & Roucou, X. (05 May 2023). OpenCustomDB: Integration of Unannotated Open Reading Frames and Genetic Variants to Generate More Comprehensive Customized Protein Databases. Journal of Proteome Research, 22 (5), 1492 - 1500. doi:10.1021/acs.jproteome.3c00054

Ritacco, C., Köse, M. C., Courtois, J., Canti, L., Beguin, C., DUBOIS, S., Vandenhove, B., Servais, S., Caers, J., Beguin, Y., Ehx, G.* , & Baron, F.*. (17 March 2023). Post-transplant cyclophosphamide prevents xenogeneic graft-versus-host disease while depleting proliferating regulatory T cells. iScience, 26 (3), 106085. doi:10.1016/j.isci.2023.106085
* These authors have contributed equally to this work.

Trofimov, A., Brouillard, P., Larouche, J.-D., Séguin, J., Laverdure, J.-P., Brasey, A., Ehx, G., Roy, D.-C., Busque, L., Lachance, S., Lemieux, S., & Perreault, C. (16 September 2022). Two types of human TCR differentially regulate reactivity to self and non-self antigens. iScience, 25 (9), 104968. doi:10.1016/j.isci.2022.104968

Apavaloaei, A., Hesnard, L., Hardy, M.-P., Benabdallah, B., Ehx, G., Thériault, C., Laverdure, J.-P., Durette, C., Lanoix, J., Courcelles, M., Noronha, N., Chauhan, K. D., Lemieux, S., Beauséjour, C., Bhatia, M., Thibault, P., & Perreault, C. (16 August 2022). Induced pluripotent stem cells display a distinct set of MHC I-associated peptides shared by human cancers. Cell Reports, 40 (7), 111241. doi:10.1016/j.celrep.2022.111241

Canti, L., Ariën, K. K., Desombere, I., Humblet-Baron, S., Pannus, P., Heyndrickx, L., HENRY, A., SERVAIS, S., WILLEMS, E., Ehx, G., Goriely, S., SEIDEL, L., Michiels, J., Willems, B., Goossens, M. E., Beguin, Y., Marchant, A., & Baron, F. (11 April 2022). Antibody response against SARS-CoV-2 Delta and Omicron variants after third-dose BNT162b2 vaccination in allo-HCT recipients. Cancer Cell, 40 (4), 335-337. doi:10.1016/j.ccell.2022.02.005

Canti, L.* , Humblet-Baron, S.* , Desombere, I., Neumann, J., Pannus, P., Heyndrickx, L., Henry, A., SERVAIS, S., WILLEMS, E., Ehx, G., Goriely, S., Seidel, L., Michiels, J., Willems, B., Liston, A., Ariën, K. K., Beguin, Y., Goossens, M. E., Marchant, A., & Baron, F. (2021). Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients. Journal of Hematology and Oncology, 14 (1), 174. doi:10.1186/s13045-021-01190-3
* These authors have contributed equally to this work.

Courtois, J., Ritacco, C., DUBOIS, S., Canti, L., Vandenhove, B., SEIDEL, L., Daulne, C., CAERS, J., SERVAIS, S., Beguin, Y., Ehx, G., & BARON, F. (2021). Itacitinib prevents xenogeneic GVHD in humanized mice. Bone Marrow Transplantation, 56, 2672-2681. doi:10.1038/s41409-021-01363-1

Ehx, G.* , Ritacco, C.* , HANNON, M., DUBOIS, S., Delens, L., WILLEMS, E., SERVAIS, S., Drion, P., BEGUIN, Y., & Baron, F. (2021). Comprehensive analysis of the immunomodulatory effects of rapamycin on human T cells in graft-versus-host disease prophylaxis. American Journal of Transplantation, 21, 2662-2674. doi:10.1111/ajt.16505
* These authors have contributed equally to this work.

Ritacco, C.* , Ehx, G.* , GREGOIRE, C., Daulne, C., WILLEMS, E., SERVAIS, S., BEGUIN, Y., & Baron, F. (2021). High proportion of terminally-differentiated regulatory T cells after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 56, 1828-1841. doi:10.1038/s41409-021-01221-0
* These authors have contributed equally to this work.

Bolomsky, A., Vogler, M., Köse, M. C., Heckman, C. A., Ehx, G., Ludwig, H., & Caers, J. (2020). MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents. Journal of Hematology and Oncology, 13 (1), 173. doi:10.1186/s13045-020-01007-9

Larouche, J.-D., Trofimov, A., Hesnard, L., Ehx, G., Zhao, Q., Vincent, K., Durette, C., Gendron, P., Laverdure, J.-P., Bonneil, E., Coté, C., Lemieux, S., Thibault, P., & Perreault, C. (2020). Widespread and tissue-specific expression of endogenous retroelements in human somatic tissues. Genome Medicine, 12 (1). doi:10.1186/s13073-020-00740-7

Noronha, N.* , Ehx, G.* , Meunier, M.-C., Laverdure, J.-P., Thériault, C., & Perreault, C. (2020). Major multilevel molecular divergence between THP-1 cells from different biorepositories. International Journal of Cancer, 147 (7), 2000-2006. doi:10.1002/ijc.32967
* These authors have contributed equally to this work.

Delens, L., Ehx, G., SOMJA, J., Vrancken, L., Belle, L., SEIDEL, L., Grégoire, C., Fransolet, G., Ritacco, C., Hannon, M., DUBOIS, S., Beguin, Y., Baron, F., & Servais, S. (2019). In Vitro Th17-Polarized Human CD4(+) T Cells Exacerbate Xenogeneic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 25, 204-215. doi:10.1016/j.bbmt.2018.10.007

Ehx, G., & Perreault, C. (2019). Discovery and characterization of actionable tumor antigens. Genome Medicine, 11 (1). doi:10.1186/s13073-019-0642-x

Grégoire, C., Ritacco, C., Hannon, M., SEIDEL, L., Delens, L., Belle, L., DUBOIS, S., Veriter, S., LECHANTEUR, C., BRIQUET, A., Servais, S., Ehx, G., Beguin, Y., & Baron, F. (2019). Comparison of Mesenchymal Stromal Cells From Different Origins for the Treatment of Graft-vs.-Host-Disease in a Humanized Mouse Model. Frontiers in Immunology, 10, 619. doi:10.3389/fimmu.2019.00619

Dupont, L., Ehx, G., Chantry, M., Monseur, C., Leduc, C., Janssen, L., Cataldo, D., Thiry, M., Jérôme, C., Thomassin, J.-M., Nusgens, B., Dubail, J., Baron, F., & Colige, A. (2018). Spontaneous atopic dermatitis due to immune dysregulation in mice lacking Adamts2 and 14. Matrix Biology, 70, 140-157. doi:10.1016/j.matbio.2018.04.002

Ehx, G., SOMJA, J., Warnatz, H.-J., Ritacco, C., HANNON, M., Delens, L., Fransolet, G., DELVENNE, P., Muller, J., BEGUIN, Y., Lehrach, H., Belle, L., Humblet-Baron, S., & BARON, F. (2018). Xenogeneic graft-versus-host disease in humanized NSG and NSG-HLA-A2/HHD mice. Frontiers in Immunology, 9, 1943. doi:10.3389/fimmu.2018.01943

Ehx, G., Fransolet, G., De Leval, L., D'Hondt, S., Lucas, S., Hannon, M., Delens, L., DUBOIS, S., Drion, P., Beguin, Y., Humblet-Baron, S., & Baron, F. (2017). Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effects. Oncoimmunology, 6:e1314425. doi:10.1080/2162402X.2017.1314425

Belle, L.* , Fransolet, G.* , Somja, J., BINSFELD, M., Delvenne, P., Drion, P., Hannon, M., BEGUIN, Y., Ehx, G.* , & Baron, F.*. (12 December 2016). Limited Impact of Imatinib in a Murine Model of Sclerodermatous Chronic Graft-versus-Host Disease. PLoS ONE, 11, 0167997. doi:10.1371/journal.pone.0167997
* These authors have contributed equally to this work.

Fransolet, G.* , Ehx, G.* , SOMJA, J., Delens, L., Hannon, M., Muller, J., DUBOIS, S., Drion, P., CAERS, J., Humblet-Baron, S., DELVENNE, P., BEGUIN, Y., Conteduca, G.* , & BARON, F.*. (04 July 2016). Azacytidine mitigates experimental sclerodermic chronic graft-versus-host disease. Journal of Hematology and Oncology, 9, 53. doi:10.1186/s13045-016-0281-2
* These authors have contributed equally to this work.

SERVAIS, S., BEGUIN, Y., Delens, L., Ehx, G., Fransolet, G., Hannon, M., WILLEMS, E., Humblet-Baron, S., Belle, L., & Baron, F. (11 May 2016). Novel approaches for preventing acute graftversus- host disease after allogeneic hematopoietic stem cell transplantation. Expert Opinion on Investigational Drugs, 9, 957-972. doi:10.1080/13543784.2016.1182498

Göktuna, S., Shostak, K., Chau, T.-L., Heukamp, L., Hennuy, B., Duong, H. Q., LADANG, A., Close, P., Klevernic, I., Olivier, F., Florin, A., Ehx, G., Baron, F., Vandereyken, M., Rahmouni, S., Vereecke, L., van Loo, G., Büttner, R., Greten, F., & Chariot, A. (2016). The Prosurvival IKK-Related Kinase IKK« Integrates LPS and IL17A Signaling Cascades to Promote Wnt-Dependent Tumor Development in the Intestine. Cancer Research, 76, 2587-99. doi:10.1158/0008-5472.CAN-15-1473

HANNON, M., BEGUIN, Y., Ehx, G., SERVAIS, S., SEIDEL, L., Graux, C., Maertens, J., Kerre, T., Daulne, C., de Bock, M., Fillet, M., ORY, A., WILLEMS, E., GOTHOT, A., Humblet-Baron, S., & BARON, F. (15 July 2015). Immune Recovery after Allogeneic Hematopoietic Stem Cell Transplantation following Flu-TBI versus TLI-ATG Conditioning. Clinical Cancer Research, 21 (14), 3131-9. doi:10.1158/1078-0432.CCR-14-3374

Ehx, G.* , Hannon, M.* , BEGUIN, Y., Humblet-Baron, S.* , & BARON, F.*. (2015). Validation of a multicolor staining to monitor phosphoSTAT5 levels in regulatory T-cell subsets. Oncotarget, 6, 43255-43266. doi:10.18632/oncotarget.6486
* These authors have contributed equally to this work.

Ehx, G.* , Gerin, S.* , Mathy, G., Franck, F., Oliveira, H. C., Vercesi, A. E., & Sluse, F. (21 July 2014). Liver proteomic response to hypertriglyceridemia in human-apolipoprotein C-III transgenic mice at cellular and mitochondrial compartment levels. Lipids in Health and Disease, 13, 116. doi:10.1186/1476-511X-13-116
* These authors have contributed equally to this work.

Baron, F., Humblet-Baron, S., Ehx, G., SERVAIS, S., HANNON, M., Belle, L., LECHANTEUR, C., BRIQUET, A., GIET, O., BAUDOUX, E., WILLEMS, E., & Beguin, Y. (2014). Thinking out of the box - New approaches to controlling GVHD. Current Hematologic Malignancy Reports, 9, 73-84. doi:10.1007/s11899-013-0187-9

Articles accepted in conference proceedings

E Silva, B., Daubry, A., Faville, C., Jassin, M., Baron, F., & Ehx, G. (2024). IFN-γ predisposes acute myeloid leukemia to therapy resistance. European Journal of Immunology. doi:10.1002/eji.202470200

Kina, E., Laverdure, J.-P., Durette, C., Lanoix, J., Courcelles, M., Zhao, Q., Apavaloaei, A., Larouche, J.-D., Hardy, M.-P., Vincent, K., Gendron, P., Hesnard, L., Ruiz Cuevas, M. V., Ehx, G., Thibault, P., & Perreault, C. (November 2022). Breast cancer immunopeptidomes contain numerous shared tumor antigens. Journal for ImmunoTherapy of Cancer, 10 (S2), 1411. doi:10.1136/jitc-2022-sitc2022.1411

Ehx, G., Nandita, N., Durette, C., Courtois, J., Hardy, M.-P., Vincent, K., Laverdure, J.-P., Lanoix, J., Baron, F., Thibault, P., & Perreault, C. (June 2022). Proteogenomic characterization of 5-azacytidine effects on acute myeloid leukemia immunopeptidome. HemaSphere, 6, 300-301. doi:10.1097/01.hs9.0000844488.25409.8e

Ruiz, M. V., Apavaloaei, A., Zhao, Q., Hardy, M.-P., Lemieux, S., Perreault, C., & Ehx, G. (August 2021). BamQuery: A new proteogenomic tool to explore the immunopeptidome and validate tumor‐specific antigens. European Journal of Immunology, 51 (S1), 60. doi:10.1002/eji.202170200

Ritacco, C., Ehx, G., Canti, L., DUBOIS, S., Vandenhove, B., SERVAIS, S., Beguin, Y., & Baron, F. (01 March 2020). Ptcy Prevents Xenogeneic Gvhd without Abrogating Gvl Effects. Biology of Blood and Marrow Transplantation, 26 (3), 168. doi:10.1016/j.bbmt.2019.12.028

Oral presentations in conferences with scientific selection committee

Beguin, C.* , Kwan, O.* , Somja, J., Dubois, S., Caers, J., Ehx, G., Dejardin, E., Ritacco, C.* , & Baron, F.*. (06 February 2026). Impact of the NF-kappa B inducing kinase inhibitor SMI1 on graft-versus-host disease [Paper presentation]. Belgian Hematology Society Annual Meeting, Bruxelles, Belgium.
* These authors have contributed equally to this work.

Beguin, C., Kwan, O., Ritacco, C., Debray, J.-C., Dejardin, E., Dubois, S., Köse, M. C., Canti, L., Courtois, J., Seidel, L., Daulne, C., Caers, J., Beguin, Y., Ehx, G., & Baron, F. (17 November 2023). TNF-α priming of human regulatory T cells does not increase their ability to prevent xenogeneic graft-versus-host disease [Paper presentation]. Congrès annuel de la Société Francophone de Greffe de Moelle et Thérapie Cellulaire, Lille, France.

Preprints

E Silva, B.* , Daubry, A.* , Faville, C.* , De Voeght, A., Foguenne, J., Jassin, M., Kwan, O., Correia Da Cruz, L., Carriglio, G., Charles, S., Baron, F., Caers, J., Gothot, A., & Ehx, G. (2026). Biases introduced by Ficoll-based isolation in acute myeloid leukemia sample analyses support the use of hemolysis. ORBi-University of Liège. https://orbi.uliege.be/handle/2268/342923. doi:10.64898/2026.02.11.705243
* These authors have contributed equally to this work.

Ruiz Cuevas, M. V., Hardy, M.-P., Larouche, J.-D., Apavaloaei, A., Kina, E., Vincent, K., Gendron, P., Laverdure, J.-P., Durette, C., Thibault, P.* , Lemieux, S.* , Perreault, C.* , & Ehx, G.*. (2022). BamQuery: a proteogenomic tool for the genome-wide exploration of the immunopeptidome. ORBi-University of Liège. https://orbi.uliege.be/handle/2268/298884. doi:10.1101/2022.10.07.510944
* These authors have contributed equally to this work.